Get to know our clinical trials
Clinical Trial - Randomized, open-label, phase 2 study of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal and fallopian tube cancer.
THE MAIN OBJECTIVE OF THIS STUDY IS TO INVESTIGATE THE EFFICACY AND SAFETY PROFILE OF MIRV WITH AN ALTERNATIVE ADMINISTRATION SCHEDULE TO THE APPROVED U.S. SCHEDULE, WITH THE AIM OF POTENTIALLY IMPROVING THE RISK-BENEFIT PROFILE. IN ADDITION, A STARTING DOSE OF MIRV WILL BE DETERMINED IN PATIENTS WITH MODERATE HEPATIC IMPAIRMENT.
Technical Summary
- RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF MIRVETUXIMAB SORAVTANSINE IN PATIENTS WITH RAPIDLY PROGRESSING, PLATINUM-RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL AND OR FALLOPIAN TUBE CANCER WITH HIGH EXPRESSION OF FOLATE RECEPTOR ALPHA, EVALUATING 2 ADMINISTRATION SCHEDULES FOR DOSE OPTIMIZATION, WITH A SEPARATE COHORT TO DETERMINE STARTING DOSE IN PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- Code EudraCT: 2024-517184-23-00
- Protocol number: IMGN853-0425
- Promoter: Abbvie farmacéutica
- Molecule/Drug: mirvetuximab soravtansina
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.